AllRock Bio Initiates Phase 2a Trial of ROC-101 for Pulmonary Hypertension Treatment#USA#Natick#Pulmonary_Hypertension#AllRock_Bio#ROC-101
AllRock Bio Initiates Phase 2a Trial of ROC-101 for Pulmonary Hypertension Treatment
AllRock Bio has commenced its Phase 2a ROCSTAR trial, administering ROC-101 to patients with pulmonary hypertension to assess safety and efficacy combined with standard therapies.
third-news.com
April 9, 2026 at 11:13 AM
AllRock Bio Initiates Phase 2a Trial of ROC-101 for Pulmonary Hypertension Treatment#USA#Natick#Pulmonary_Hypertension#AllRock_Bio#ROC-101
AllRock Bio Unveils Promising ROC-101 Phase 1 Data at ERS Congress#USA#Natick#AllRock_Bio#ROC-101#ERS_Congress
AllRock Bio Unveils Promising ROC-101 Phase 1 Data at ERS Congress
AllRock Bio presents Phase 1 data for ROC-101 at ERS Congress, showing promising safety and efficacy for PAH and ILD-PH treatments.
third-news.com
September 29, 2025 at 10:14 AM
AllRock Bio Unveils Promising ROC-101 Phase 1 Data at ERS Congress#USA#Natick#AllRock_Bio#ROC-101#ERS_Congress
AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment#United_States#Natick#Pulmonary_Hypertension#AllRock_Bio#ROC-101
AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment
AllRock Bio Inc. has successfully raised $50 million to advance ROC-101, its lead clinical candidate aimed at treating pulmonary hypertension and interstitial lung disease.
third-news.com
September 16, 2025 at 11:11 AM
AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment#United_States#Natick#Pulmonary_Hypertension#AllRock_Bio#ROC-101